Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASMBNASDAQ:CPIXNASDAQ:NKTRNASDAQ:OMER On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASMBAssembly Biosciences$18.15-0.8%$14.84$7.75▼$19.93$138.55M0.6227,558 shs15,693 shsCPIXCumberland Pharmaceuticals$3.15-7.6%$4.80$1.04▼$7.25$51.02M-0.39870,485 shs120,657 shsNKTRNektar Therapeutics$24.65-3.4%$12.71$6.48▼$37.38$316.75M0.94476,131 shs994,109 shsOMEROmeros$3.20+3.6%$4.13$2.95▼$13.60$181.05M2.16724,839 shs536,692 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASMBAssembly Biosciences-0.82%+6.26%+19.41%+108.38%+49.38%CPIXCumberland Pharmaceuticals-7.62%+17.54%-45.50%-25.53%+105.88%NKTRNektar Therapeutics-3.45%-16.95%+119.26%+197.76%+26.41%OMEROmeros+3.59%-3.58%+1.94%-54.66%-17.50%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASMBAssembly Biosciences3.6903 of 5 stars3.33.00.04.71.70.00.0CPIXCumberland Pharmaceuticals0.5477 of 5 stars0.03.00.00.02.11.70.0NKTRNektar Therapeutics4.6656 of 5 stars3.55.00.04.23.72.50.0OMEROmeros3.7148 of 5 stars3.40.00.04.41.91.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASMBAssembly Biosciences 2.67Moderate Buy$33.0081.82% UpsideCPIXCumberland Pharmaceuticals 0.00N/AN/AN/ANKTRNektar Therapeutics 3.00Buy$84.17241.45% UpsideOMEROmeros 2.83Moderate Buy$18.00462.32% UpsideCurrent Analyst Ratings BreakdownLatest NKTR, OMER, ASMB, and CPIX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2025OMEROmerosD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.006/27/2025OMEROmerosHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.006/24/2025NKTRNektar TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy$60.00 ➝ $100.006/24/2025NKTRNektar TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$120.006/10/2025OMEROmerosHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$9.005/16/2025OMEROmerosNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold5/13/2025OMEROmerosD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.005/12/2025NKTRNektar TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform5/7/2025OMEROmerosD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.004/11/2025NKTRNektar TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$15.00 ➝ $30.004/11/2025OMEROmerosD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.00(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASMBAssembly Biosciences$32.15M4.31N/AN/A$5.25 per share3.46CPIXCumberland Pharmaceuticals$37.87M1.24$0.24 per share13.26$1.61 per share1.96NKTRNektar Therapeutics$87.25M3.51N/AN/A$4.94 per share4.99OMEROmerosN/AN/AN/AN/A($3.15) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASMBAssembly Biosciences-$40.18M-$6.23N/AN/AN/A-124.15%-131.77%-36.81%8/6/2025 (Estimated)CPIXCumberland Pharmaceuticals-$6.48M-$0.25N/A∞N/A-7.98%6.92%2.33%8/5/2025 (Estimated)NKTRNektar Therapeutics-$118.96M-$9.60N/AN/AN/A-152.49%-329.54%-55.24%8/6/2025 (Estimated)OMEROmeros-$156.82M-$2.65N/AN/AN/AN/AN/A-59.68%8/6/2025 (Estimated)Latest NKTR, OMER, ASMB, and CPIX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025OMEROmeros-$0.60-$0.65-$0.05-$0.58$0.40 millionN/A5/8/2025Q1 2025ASMBAssembly Biosciences-$2.01-$1.17+$0.84-$1.17$7.41 million$9.42 million5/8/2025Q1 2025NKTRNektar Therapeutics-$2.70-$3.30-$0.60-$0.24$15.61 million$10.46 million5/6/2025Q1 2025CPIXCumberland PharmaceuticalsN/A$0.15N/A$0.08N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASMBAssembly BiosciencesN/AN/AN/AN/AN/ACPIXCumberland PharmaceuticalsN/AN/AN/AN/AN/ANKTRNektar TherapeuticsN/AN/AN/AN/AN/AOMEROmerosN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASMBAssembly BiosciencesN/A2.052.05CPIXCumberland Pharmaceuticals0.181.251.09NKTRNektar TherapeuticsN/A3.243.24OMEROmerosN/A1.161.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASMBAssembly Biosciences19.92%CPIXCumberland Pharmaceuticals15.51%NKTRNektar Therapeutics75.88%OMEROmeros48.79%Insider OwnershipCompanyInsider OwnershipASMBAssembly Biosciences5.30%CPIXCumberland Pharmaceuticals44.85%NKTRNektar Therapeutics5.25%OMEROmeros12.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASMBAssembly Biosciences1007.64 million7.23 millionOptionableCPIXCumberland Pharmaceuticals8014.96 million8.25 millionOptionableNKTRNektar Therapeutics22012.41 million11.76 millionOptionableOMEROmeros21058.59 million51.04 millionOptionableNKTR, OMER, ASMB, and CPIX HeadlinesRecent News About These CompaniesOmeros (NASDAQ:OMER) Receives Buy Rating from D. Boral CapitalJune 30, 2025 | marketbeat.comOmeros Seeks EMA Approval For Narsoplimab After Data Shows 3X Survival BoostJune 30, 2025 | msn.comWall Street Zen Downgrades Omeros (NASDAQ:OMER) to SellJune 29, 2025 | americanbankingnews.comOmeros (NASDAQ:OMER) Downgraded to "Sell" Rating by Wall Street ZenJune 27, 2025 | marketbeat.comOmeros (OMER) Eyes European Approval for Key Drug Narsoplimab | OMER Stock NewsJune 27, 2025 | gurufocus.comOmeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMAJune 27, 2025 | businesswire.comOmeros Co. (NASDAQ:OMER) Given Consensus Rating of "Moderate Buy" by BrokeragesJune 16, 2025 | marketbeat.com‘Hundreds’ of documents to review in Omeros money laundering case, defence lawyer tells courtJune 12, 2025 | couriermail.com.auCWhat is HC Wainwright's Forecast for Omeros FY2025 Earnings?June 12, 2025 | marketbeat.comHC Wainwright & Co. Initiates Coverage of Omeros (OMER) with Buy RecommendationJune 12, 2025 | msn.comOmeros Stock Short Interest Report | NASDAQ:OMER | BenzingaJune 11, 2025 | benzinga.comHC Wainwright Predicts Omeros' Q2 Earnings (NASDAQ:OMER)June 11, 2025 | marketbeat.comOmeros Analyst Sees $1 Billion Potential For Narsoplimab Before FDA DecisionJune 10, 2025 | benzinga.comBrokers Set Expectations for Omeros FY2026 EarningsJune 10, 2025 | marketbeat.comOmeros (NASDAQ:OMER) Earns Buy Rating from Analysts at HC WainwrightJune 10, 2025 | marketbeat.comOmeros (NASDAQ:OMER) Lowered to Sell Rating by Wall Street ZenJune 6, 2025 | marketbeat.comDown 54.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Omeros (OMER)June 3, 2025 | zacks.comOmeros: On The Brink As It Awaits Its Fall PDUFA For A Potential BlockbusterMay 27, 2025 | seekingalpha.comOmeros: On The Brink As It Awaits Its Fall PDUFA For A Potential BlockbusterMay 27, 2025 | seekingalpha.comJulian Lucas on Hilton Als’s “The Islander”May 25, 2025 | newyorker.comNOmeros Corporation (NASDAQ:OMER) Q1 2025 Earnings Call TranscriptMay 17, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesTop 3 Bank Stocks to Watch as Fed Rate Cuts LoomBy Chris Markoch | June 25, 2025View Top 3 Bank Stocks to Watch as Fed Rate Cuts LoomBroadcom Slides on Solid Earnings, AI Outlook Still StrongBy Leo Miller | June 6, 2025View Broadcom Slides on Solid Earnings, AI Outlook Still StrongBroadcom’s Big VMware Update: A Threat to Public Cloud Giants?By Leo Miller | June 28, 2025View Broadcom’s Big VMware Update: A Threat to Public Cloud Giants?GE Aerospace Turns Engines Into Long-Term ProfitsBy Jeffrey Neal Johnson | June 21, 2025View GE Aerospace Turns Engines Into Long-Term ProfitsRed Robin's Comeback: Q1 Earnings Spark Investor HopesBy Jeffrey Neal Johnson | June 5, 2025View Red Robin's Comeback: Q1 Earnings Spark Investor HopesASMB, NKTR, OMER, and CPIX Company DescriptionsAssembly Biosciences NASDAQ:ASMB$18.15 -0.15 (-0.82%) As of 07/3/2025 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.Cumberland Pharmaceuticals NASDAQ:CPIX$3.15 -0.26 (-7.62%) As of 07/3/2025 03:23 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.Nektar Therapeutics NASDAQ:NKTR$24.65 -0.88 (-3.45%) Closing price 07/3/2025 03:57 PM EasternExtended Trading$24.72 +0.08 (+0.30%) As of 07/3/2025 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.Omeros NASDAQ:OMER$3.20 +0.11 (+3.59%) Closing price 07/3/2025 03:57 PM EasternExtended Trading$3.17 -0.04 (-1.09%) As of 07/3/2025 04:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
